TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CD8 Reactivity to Microorganisms in Blood and Breast Milk

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
-INCLUSION CRITERIA:~1. Age 18+ years.~2. Willing to allow storage of blood, breast milk, and cells for future research.~3. Willing to have genetic testing performed.~4. Meets one of the 3 following criteria:~   1. Confirmed exposure:~      -Exposure has been verifiably documented (eg, receiving an immunization or DNCB sensitization treatment).~      OR~      -Clinical history is consistent with established epidemiology of the microbe of interest (eg, documentation of past infection; or to a lesser priority travel to endemic areas or living with an individual that suffers from chronic infection with the targeted microbe).~      AND~      -Positive results on established clinical immunity tests (eg, viral RNA, antibody titers, etc).~  2. Suspected exposure: Clinical history is consistent with established epidemiology of the microbe of interest (eg, travel to endemic areas, documentation of past infection) but no established clinical assay exists to verify exposure.~  3. Non-exposed: Absence of exposure to targeted microorganisms as measured by lack of exposure to infected individuals, lack of travel to endemic areas, no immunization history, negative screening tests, or other methods of establishing exposure history to mucosal microbial agents.~EXCLUSION CRITERIA:~1. Active use of immunosuppressive medications.~2. Any condition that, in the opinion of the investigator, contraindicates participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Controls (Type: None): non exposed controls
- donors with naturally enriched antimicrobial blood samples and (Type: None): Donors with naturally enriched antimicrobial blood samples an breast milk, Comparisons will be made with non exposed controls.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Total Knee Arthroplasty Functional Outcomes Study Research Design

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or non-pregnant female age 18 years or older at time of study~* Patient is a candidate for a total knee arthroplasty~* Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation~Exclusion Criteria:~* Patients with a primary diagnosis other than osteoarthritis of the knee as determined by an orthopedic surgeon~* Patients who have had any previous lower extremity procedure~* Patients with a BMI greater than or equal to 40~* Patients with an active infection within the affected knee joint~* Patients with a neuromuscular or neurosensory deficiency that may limit the ability of the patient to evaluate the safety and efficacy of the device~* Patients diagnosed with systemic disease or metabolic disorder leading to progressive bone deterioration (e.g. Lupus Erythematosus, Paget's disease)~* Patients immunologically suppressed or receiving chronic steroids in excess of normal physiological requirements (e.g. greater than 30 days)~* Patients with a known sensitivity to device materials~* Non-English speaking patients~* Patient is a prisoner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Total knee arthroplasty patients (Type: None): ConforMIS iTotal (CR) knee implant system and off-the-shelf knee implant systems from various manufacturers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject's age is greater than or equal to 18 years~* Subject is patient in neuro intensive care unit at time of PICC placement~Exclusion Criteria:~* Acute trauma to the upper extremity harboring the PICC~* Current use of prophylactic anticoagulation~* Inability to fit the SCD on the arm because of arm size~* Documented previous upper extremity DVT in the arm harboring the PICC line

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pneumatic SCD (Type: ACTIVE_COMPARATOR): Use of pneumatic SCD (VenaFlow System - DJO Global) on upper extremity with PICC line inserted.
- Non-SCD group (Type: NO_INTERVENTION): Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Intrapartum Ultrasound in Instrumental Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women at term, in labor (≥ 37 weeks of gestation dated by a first trimester ultrasound~* live singleton pregnancy~* fetus in a cephalic presentation~* in the second stage of labor, after the decision to perform an instrumental delivery~Exclusion Criteria:~* fetal malformations~* emergency situation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study group (Type: EXPERIMENTAL): The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
- Control group (Type: NO_INTERVENTION): The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed aplastic anemia Must have related donor with a genotypic 6 out of 6 HLA A, B, and DR match OR Bone marrow transplant failure Must have related donor with at least a 5 out of 6 HLA match OR Must have an unrelated donor with at least a 5 out of 6 HLA match~PATIENT CHARACTERISTICS: Age: 15 to 55 Performance status: Aplastic anemia patients: Karnofsky 80-100% Graft failure patients: Karnofsky 20-100% Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Aplastic anemia patients: Bilirubin no greater than 2.0 mg/dL SGOT/SGPT no greater than 3 times normal PT/PTT normal (except when aplastic anemia secondary to viral hepatitis) Graft failure patients: Mild to severe venoocclusive disease allowed Renal: Aplastic anemia patients: Creatinine no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: Aplastic anemia patients: Left ventricular ejection fraction at least 45% by MUGA or echocardiography No myocardial infarction within the past 6 months No uncontrolled arrhythmias Pulmonary: Aplastic anemia patients: FEV1 and DLCO at least 50% predicted Other: Aplastic anemia patients: No uncontrolled diabetes mellitus or thyroid disease No active serious infections HIV negative Not pregnant or nursing Negative pregnancy test No psychosocial problem that would preclude study compliance~PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Addition of Non-Invasive Ventilation To Airway Clearance Techniques In Adults With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis (confirmed by genotype or a sweat sodium concentration of \>70mmol/l or sweat chloride of \>60mmol/l)~* Sixteen years of age or over~* Patients admitted to the Royal Brompton Hospital with a pulmonary exacerbation of which is resolving. Patients will be considered for inclusion from day 7 of treatment to 3 days prior to discharge (as determined by a member of the cystic fibrosis medical team and have spirometric values within 20% of the mean of the last two stable recordings (at least 1 month apart)~* Patients with an established airway clearance regime that they have used for 3 months or more~Exclusion Criteria:~* Current moderate haemoptysis (greater than streaking in the sputum)~* Current pneumothorax or history of pneumothorax in the 3 months prior to consideration for the study~* Current dependency on positive pressure support with airway clearance via the IPPB (Intermittent Positive Pressure Breathing) machine or NIV~* Previous history of spontaneous rib fractures~* Pregnancy~* Inability to give consent for treatment or measurement~* Current participation in another study~* If the patient requires more than 2 airway clearance sessions a day

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal airway clearance (Type: EXPERIMENTAL): The patients usual airway clearance technique
- Non-Invasive Ventilation (Type: EXPERIMENTAL): The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 positive inpatient (PCR or other certified test mandatory)~* Inpatient showing at least one of the following criterion: Abnormal respiratory auscultation AND SpO2 \< 94% without oxygen therapy, OR Acute Respiratory failure requiring either oxygen therapy or high-flow oxygen therapy or non-invasive respirator and/or invasive respirator.~Exclusion Criteria:~* Inpatient requiring legal protection~* Pregnant or breastfeeding woman~* Intensive care inpatient or patient undergoing surgery~Secondary non inclusion criteria :~- Unintentional blinding removal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Auricular neuromodulation (Type: EXPERIMENTAL): None
- Control (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* (1) Patients who provided informed consent~* (2) Patients who are diagnosed as membranous nephropathy by renal biopsy~* (3) 18 years of age or older, male or female~Exclusion Criteria:~* (1) identification of Secondary factors such as infectious diseases, rheumatic diseases, tumors, drugs and so on~* (2) Previous medicine history of immunosuppressive medication and corticosteroids~* (3) Patients who are not expected to complete 6 months of follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cyclophosphamide (Type: None): Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
- Cyclosporin (Type: None): Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence of Lactose Intolerance Following Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients planned to undergo a stem cell transplant.~Exclusion Criteria:~* Refusal to participate~* Unable to perform breath tests on request (generally under the age of 4 years.)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged =/\> 18 years~* Subjects with advanced, histologically or cytologically confirmed advanced malignancies (solid tumors), refractory to any standard therapy, have no standard therapy available, or subjects actively refused any standard treatment and / or if, in the judgment of the investigator, experimental treatment is clinically and ethically acceptable.~* For the expansion cohort: women with histologically or cytologically confirmed triple negative breast cancer (TNBC)~* Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Life expectancy of at least 12 weeks~* Adequate bone marrow, liver, and renal functions~Exclusion Criteria:~* Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study~* Evidence of peripheral neuropathy of Grade \> 2~* History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class \> II, unstable angina (anginal symptoms at rest), new-onset angina (within the past 3 months before study entry), myocardial infarction within the past 3 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted)~* Prior treatment with more than 3 lines of cytostatic therapies for metastatic disease unless specifically agreed between investigator and sponsor. Subjects with a history of any prior Grade =/\> 3 toxicity associated with taxane treatment will be excluded.~* Uncontrolled hypertension defined as systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg, despite optimal medical management~* Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C~* History of human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY1161909 + Paclitaxel (Type: EXPERIMENTAL): Participants received oral doses of BAY1161909 starting from 0.75 mg twice daily, from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in combination with weekly intravenous paclitaxel on D1, D8, and D15 of the 28-day cycles. For single-dose Pharmacokinetic (PK) cohort: in Cycle 1, participants received a single oral dose of 6 mg BAY1161909 on C1D1 with no BAY1161909 dosing for the remainder of Cycle 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics for Prevention Neonatal Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All newborn infants in the community \>24 hours and \<72 hours of age~* 2000 g at birth~* Breastfeeding begun by 24 hr of life~* Able to tolerate oral feeds~* Informed consent by parent or guardian~Exclusion Criteria:~* Evidence or suspicion of clinical sepsis before the baby is randomized~* Not on breast feeding by 24 hr~* Inability to establish oral feeds (in case of maternal death or ailment)~* Presence of major congenital anomalies

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 3 Days
- Healthy Volunteers: t

Study Arms:
- Probiotic group (Type: EXPERIMENTAL): Once daily oral administration of a probiotic preparation (1 billion cells of Lactobacillus plantarum and 150 mg of fructooligosaccharides) for one week to newborn infants
- Placebo (Type: PLACEBO_COMPARATOR): Once daily oral administration of maltodextrin for one week to newborn infants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~A subject must satisfy all of the following criteria to be eligible to participate in this study:~1. Latino ethnicity. Latino ethnic background will be defined as a geographic, historical, and cultural heritage shared among persons from Spanish-speaking countries in South and Central America, Mexico, and the Caribbean. Both parents and all grandparents of the participant have to be Latino, with Spanish as the primary language. Participants have to be white; native aboriginal Indians, Asians, and blacks will be excluded.~2. Age greater than or equal to 18 years.~3. Documentation of hepatitis C infection by demonstration of a positive test for hepatitis C antibody and HCV RNA level of greater than or equal to 2,000 IU/mL.~4. Documentation of HIV-1 infection in the second group of co-infected participants by a licensed enzyme-linked immunosorbent assay and confirmed by a Western blot or by HIV polymerase chain reaction positive.~5. Participants with HIV: CD4+ cell counts greater than or equal to 100 cells/mm(3) or CD4+ cell percentage greater than or equal to 14%.~6. Ability to provide informed consent and willingness to comply with the study requirements, storage of blood samples and clinic policies.~7. Participants must have a primary care physician managing medical problems.~8. For HIV infected participants, care provided by a primary physician must be consistent with the current DHHS guidelines. For those on therapy, HAART will be provided by their physician.~9. Willing to undergo genetic testing~10. About to start HCV treatment (with or without direct acting agents DAAs)~EXCLUSION CRITERIA:~A subject will be ineligible to participate in this study if any of the following criteria are met:~1. Unable to comply with research study visits~2. Have any condition that the investigator considers a contraindication to study participation.~3. Pregnant or breastfeeding women.~4. Patients with poor venous access

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Hepatitis C (Type: None): latino participants with Hepatitis C

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues